The current multidrug resistant Escherichia coli pandemic: exploring novel therapies against the predominant culprit E. coli ST131.

当前的多重耐药大肠杆菌大流行：探索针对主要罪魁祸首大肠杆菌 ST131 的新疗法。

• 批准号: nhmrc : 1069370
• 负责人: Prof Mark Schembri
• 金额: $ 34.16万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/current-multidrug-resistant-coli-st131/455391
• 关键词: current; multidrug; resistant; Escherichia; coli

Escherichia coli ST131 is a pandemic superbug. Like MRSA, E. coli ST131 infections are resistant to multiple antibiotics and can become life threatening. This study will show how adhesion can be the 'Achilles' heel' of this global pathogen and how blocking E. coli ST131 adhesion offers an alternative therapy for multidrug resistant human infections. As we are left with no effective antimicrobials to treat E. coli ST131 infections, this work will provide novel outcomes that are sorely needed.

大肠杆菌ST 131是一种流行性超级细菌。如MRSA、E.大肠杆菌ST 131感染对多种抗生素具有耐药性，并可能危及生命。这项研究将显示粘附如何成为这种全球病原体的“阿喀琉斯之踵”，以及如何阻断E。大肠杆菌ST131粘附为多重耐药的人类感染提供了一种替代疗法。由于我们没有有效的抗生素来治疗E。大肠杆菌ST131感染，这项工作将提供迫切需要的新成果。